Interim data from POLB 001 TOPICAL clinical trial
Poolbeg Pharma PLC announced a significant milestone for its TOPICAL clinical trial with a positive interim safety cohort review, allowing the trial to proceed as planned without protocol changes. Patient recruitment is ongoing at UK sites, with further patient enrollment and site activation anticipated. The company is focused on generating additional data for prospective partners, highlighting the potential of bispecific antibodies in cancer treatment and the importance of an effective Cytokine Release Syndrome preventative therapy. Poolbeg Pharma will host an investor presentation today, September 24, 2026, at 2:00 PM.
Select text to share a quote on X · sign in to keep highlights & notes in your POLB notes
24 September 2026 - Poolbeg Pharma (AIM: POLB, 'Poolbeg' or the 'Company'), a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field, announces that the ongoing TOPICAL clinical trial will proceed as planned following a positive review of data from the interim safety cohort. The completion of this review represents an important milestone for the TOPICAL trial.
The review recommended that the trial continue as planned, with no changes required to the study protocol. Patient recruitment is continuing across leading UK clinical sites, with further patients expected to be enrolled and additional sites activated.
The Company looks forward to generating further data and sharing more detail with prospective partners. Bispecific antibodies are becoming increasingly important in the treatment of cancer, and an effective CRS preventative therapy could represent an important advance for patients, clinicians and healthcare systems.
Jeremy Skillington, PhD, Chief Executive Officer of Poolbeg Pharma, said: “The data from the interim cohort represent a significant milestone for the TOPICAL trial. The positive recommendation to continue the study as planned provides further confidence as we advance the POLB 001 programme.
“We are building momentum across the study, with recruitment continuing at leading UK clinical sites, further patients expected to be enrolled and additional sites activated. We look forward to generating further clinical data and sharing more detail with prospective partners as we continue discussions around the POLB 001 opportunity.”
Investor presentation
Poolbeg Pharma will provide a live presentation via the Investor Meet Company platform today, 24 September 2026 at 2:00pm.
The presentation is open to analysts and investors, those who already follow Poolbeg on the Investor Meet Company platform will automatically be invited. Investors can sign up to Investor Meet for free and add Poolbeg Pharma plc to their company dashboard here.
The TOPICAL trial is evaluating POLB 001 as a preventative therapy for Cytokine Release Syndrome (“CRS”) in patients with relapsed/refractory multiple myeloma receiving the approved bispecific antibody teclistamab.
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.